<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <title>DSpace Community:</title>
  <link rel="alternate" href="http://repository.usmf.md:80/handle/20.500.12710/32503" />
  <subtitle />
  <id>http://repository.usmf.md:80/handle/20.500.12710/32503</id>
  <updated>2026-04-08T21:07:21Z</updated>
  <dc:date>2026-04-08T21:07:21Z</dc:date>
  <entry>
    <title>Metagenomics at the interface of diagnostics and surveillance: a near-term perspective</title>
    <link rel="alternate" href="http://repository.usmf.md:80/handle/20.500.12710/32511" />
    <author>
      <name>CADAR, Dániel</name>
    </author>
    <id>http://repository.usmf.md:80/handle/20.500.12710/32511</id>
    <updated>2026-01-26T11:29:01Z</updated>
    <published>2026-01-01T00:00:00Z</published>
    <summary type="text">Title: Metagenomics at the interface of diagnostics and surveillance: a near-term perspective
Authors: CADAR, Dániel
Abstract: Introduction The global landscape of infectious diseases is undergoing rapid and profound&#xD;
change. Increased human mobility, climate-driven shifts in vector ecology,&#xD;
intensified human-animal-environment interactions, and geopolitical instability have collectively amplified the risk of emerging and re-emerging infectious diseases. At the same time, public health systems are increasingly&#xD;
confronted with pathogens that are unexpected, genetically diverse, or poorly represented in existing diagnostic panels. These developments highlight&#xD;
the growing limitations of exclusively targeted diagnostic approaches and&#xD;
underscore the need for broader, more adaptive tools.&#xD;
In this context, metagenomic sequencing has emerged as a transformative&#xD;
technology. By enabling unbiased detection and genomic characterization of&#xD;
pathogens directly from clinical, environmental, or animal samples, metagenomics offers capabilities that extend far beyond conventional diagnostics.&#xD;
While historically confined to research and outbreak investigations, metagenomics is now approaching a level of maturity that warrants serious consideration for integration into routine diagnostics and risk-oriented surveillance frameworks.</summary>
    <dc:date>2026-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Astaxanthin and cellular metabolites production in Haematococcus lacustris exposed to silver nanoparticles</title>
    <link rel="alternate" href="http://repository.usmf.md:80/handle/20.500.12710/32510" />
    <author>
      <name>Cepoi, Liliana</name>
    </author>
    <author>
      <name>Rudi, Ludmila</name>
    </author>
    <author>
      <name>Chiriac, Tatiana</name>
    </author>
    <author>
      <name>Miscu, Vera</name>
    </author>
    <author>
      <name>Plîngău, Ecaterina</name>
    </author>
    <id>http://repository.usmf.md:80/handle/20.500.12710/32510</id>
    <updated>2026-01-26T11:23:47Z</updated>
    <published>2026-01-01T00:00:00Z</published>
    <summary type="text">Title: Astaxanthin and cellular metabolites production in Haematococcus lacustris exposed to silver nanoparticles
Authors: Cepoi, Liliana; Rudi, Ludmila; Chiriac, Tatiana; Miscu, Vera; Plîngău, Ecaterina
Abstract: Abstract. Introduction Silver nanoparticles (AgNPs) can modulate microalgal metabolism in a dose-dependent and&#xD;
stage-specific manner. Haematococcus lacustris, a key astaxanthin-producing microalga, is highly&#xD;
sensitive to environmental stressors that regulate the transition from the green vegetative stage to&#xD;
the red aplanospore stage.&#xD;
Material and methods The effects of 10 nm and 20 nm citrate-stabilized AgNPs (0.01–5 mg L-1) were assessed on biomass,&#xD;
cellular metabolites, photosynthetic pigments, lipids, and astaxanthin. Nanoparticles were introduced on day 3, with analyses performed at the end of the green (day 9) and red stages (day 16).&#xD;
Results Low to moderate AgNPs concentrations (0.01–1 mg L-1) increased biomass, proteins, carbohydrates,&#xD;
and lipids during the green stage, while 5 mg L-1 inhibited growth and pigments and elevated MDA&#xD;
levels. In the red stage, all concentrations reduced final biomass; however, 10 nm AgNPs at 0.01–&#xD;
0.5 mg L-1 boosted astaxanthin (by up to ~30%) and lipids (by up to ~96%). Higher doses, along with&#xD;
all 20 nm AgNP treatments, suppressed astaxanthin accumulation.&#xD;
Conclusions H. lacustris exhibits a hormetic response to AgNPs: mild exposure stimulates key metabolites, while&#xD;
higher concentrations become inhibitory. Nanoparticle size, dose, and timing are crucial for precisely directing metabolic pathways and improving astaxanthin yield.; Abstract&#xD;
Introducere Nanoparticulele de argint (AgNPs) pot modula metabolismul microalgelor într-un mod dependent&#xD;
de concentrație și de stadiul fiziologic. Haematococcus lacustris, un important producător de astaxantină, prezintă o sensibilitate sporită la factorii de stres care reglează tranziția de la faza de&#xD;
celule verzi vegetative la cea de aplanospori roșii.&#xD;
Material și metode Au fost evaluate efectele AgNP-urilor de 10 nm și 20 nm (0,01–5 mg L-1) asupra biomasei, metaboliților celulari, pigmenților fotosintetici, lipidelor și astaxantinei. Nanoparticulele au fost adăugate în&#xD;
ziua a 3-a, iar analizele au fost efectuate la sfârșitul fazei de celule vegetative (ziua a 9-a) și al fazei&#xD;
de aplanospori (ziua a 16-a).&#xD;
Rezultate Concentrațiile mici și moderate de AgNPs (0,01–1 mg L-1) au stimulat biomasa, proteinele, carbohidrații și lipidele în faza de celule vegetative, în timp ce 5 mg L-1au inhibat creșterea și conținutul de&#xD;
pigmenți și au crescut nivelul MDA. În faza de aplanospori, toate concentrațiile au redus biomasa&#xD;
finală; totuși, AgNP de 10 nm la 0,01–0,5 mg L-1 au intensificat sinteza de astaxantină (până la ~30%)&#xD;
și de lipide (până la ~96%). Dozele mai mari și toate tratamentele cu AgNPs de 20 nm au redus&#xD;
semnificativ astaxantina.&#xD;
Concluzii H. lacustris manifestă un răspuns hormetic la AgNPs: expunerea moderată stimulează metaboliții valoroși, în timp ce concentrațiile ridicate devin inhibitoare. Dimensiunea nanoparticulelor, doza&#xD;
aplicată și durata expuneriit constituie factori determinanți în modularea controlată a metabolismului celular și în optimizarea producției de astaxantină.</summary>
    <dc:date>2026-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Clinical, biochemical, and genetic distinctions in patients with mitochondrial involvement versus other genetic disorders</title>
    <link rel="alternate" href="http://repository.usmf.md:80/handle/20.500.12710/32509" />
    <author>
      <name>Secu, Doina</name>
    </author>
    <author>
      <name>Blăniță, Daniela</name>
    </author>
    <author>
      <name>Ușurelu, Natalia</name>
    </author>
    <author>
      <name>Sacară, Victoria</name>
    </author>
    <id>http://repository.usmf.md:80/handle/20.500.12710/32509</id>
    <updated>2026-01-26T11:16:16Z</updated>
    <published>2026-01-01T00:00:00Z</published>
    <summary type="text">Title: Clinical, biochemical, and genetic distinctions in patients with mitochondrial involvement versus other genetic disorders
Authors: Secu, Doina; Blăniță, Daniela; Ușurelu, Natalia; Sacară, Victoria
Abstract: Abstract Introduction Mitochondrial diseases are clinically and genetically heterogeneous disorders characterized by&#xD;
respiratory chain dysfunction, often mimicking other multisystem genetic conditions, necessitating&#xD;
an integrated clinical, biochemical, and molecular diagnosis. This study aims to compare the clinical,&#xD;
biochemical, and genetic profiles of patients with mitochondrial involvement and those with other&#xD;
inherited genetic disorders.&#xD;
Material and methods We analyzed 81 patients with suspected mitochondrial disease (Nijmegen Mitochondrial Disease&#xD;
Score ≥3), categorized into Group 1 (mitochondrial involvement) and Group 2 (other inherited&#xD;
disorders). Clinical, biochemical, instrumental, and molecular evaluations were performed using&#xD;
qPCR-HRM and Sanger sequencing, with data analyzed through descriptive statistics and nonparametric&#xD;
tests.&#xD;
Results Group 1 showed significantly higher rates of severe neuromuscular impairment, skill regression,&#xD;
ocular abnormalities, elevated plasma lactate and alanine, and characteristic neuroimaging&#xD;
findings, including basal ganglia abnormalities and cerebral-cerebellar atrophy. Genetic analysis&#xD;
identified phenotype-associated mutations in 32 patients, primarily affecting Complex I and V&#xD;
subunits and mitochondrial RNA genes, often involving multiple respiratory chain sites. Group 2&#xD;
comprised a range of genetically confirmed non-mitochondrial disorders, identified through&#xD;
targeted genomic testing.&#xD;
Conclusions This study highlights the crucial role of integrated clinical, biochemical, and genomic approaches,&#xD;
emphasizing the importance of comprehensive molecular testing and multidisciplinary evaluation&#xD;
in addressing the diagnostic complexities of overlapping genetic disorders.; Abstract Introducere Bolile mitocondriale reprezintă tulburări clinice și genetice eterogene, caracterizate prin disfuncția&#xD;
lanțului respirator, frecvent mimând alte afecțiuni genetice multisistemice, ceea ce impune un&#xD;
diagnostic integrat clinic, biochimic și molecular. Acest studiu își propune să compare profilurile&#xD;
clinice, biochimice și genetice ale pacienților cu afectare mitocondrială și ale celor diagnosticați&#xD;
cu alte boli genetice ereditare.&#xD;
Material și metode Au fost analizați 81 de pacienți cu suspiciune de boală mitocondrială (Scor clinic Nijmegen ≥3),&#xD;
împărțiți în două grupuri-țintă: grupul 1 (afectare mitocondrială) și grupul 2 (alte afecțiuni ereditare).&#xD;
Evaluările clinice, biochimice, instrumentale și moleculare au inclus qPCR-HRM și secvențierea Sanger,&#xD;
iar datele au fost analizate prin statistica descriptivă și teste neparametrice.&#xD;
Rezultate Grupul 1 a prezentat rate semnificativ mai mari de afectare neuromusculară severă: pierderea achizițiilor&#xD;
motorii, anomalii oculare, lactat și alanină plasmatică crescute, precum și modificări neuroimagistice&#xD;
caracteristice (afectarea ganglionilor bazali, atrofie cerebrală și cerebeloasă). Testele&#xD;
genetice au identificat mutații asociate fenotipului la 32 dintre pacienți, predominant în subunitățile&#xD;
Complexelor I și V și genele ARN mitocondrial, adesea cu implicare concomitentă a mai multor&#xD;
complexe respiratorii. Grupul 2 a inclus o varietate de afecțiuni genetice non-mitocondriale, confirmate&#xD;
prin teste genomice țintite.&#xD;
Concluzii Studiul subliniază rolul esențial al abordării integrate clinic, biochimic și genomic, accentuând testarea&#xD;
moleculară completă și evaluarea multidisciplinară pentru a depăși complexitatea diagnosticului&#xD;
în afecțiunile genetice suprapuse.</summary>
    <dc:date>2026-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Single nucleotide polymorphism test for rapid detection of SARS-CoV-2 linеages in the Republic of North Macedonia</title>
    <link rel="alternate" href="http://repository.usmf.md:80/handle/20.500.12710/32508" />
    <author>
      <name>Matevska, Gala</name>
    </author>
    <author>
      <name>Boshevska, Golubinka</name>
    </author>
    <author>
      <name>Jancheska, Elizabeta</name>
    </author>
    <author>
      <name>Karevska, Teodora</name>
    </author>
    <author>
      <name>Vukovikj, Maja</name>
    </author>
    <id>http://repository.usmf.md:80/handle/20.500.12710/32508</id>
    <updated>2026-01-26T10:54:57Z</updated>
    <published>2026-01-01T00:00:00Z</published>
    <summary type="text">Title: Single nucleotide polymorphism test for rapid detection of SARS-CoV-2 linеages in the Republic of North Macedonia
Authors: Matevska, Gala; Boshevska, Golubinka; Jancheska, Elizabeta; Karevska, Teodora; Vukovikj, Maja
Abstract: Abstract&#xD;
Introduction The coronavirus pandemic represents one of the most significant medical crises in recent history;&#xD;
therefore, rapid virus detection has become a critical component of public health practice. As&#xD;
the virus has undergone continuous mutations, the emergence of new variants has resulted in&#xD;
altered transmission dynamics, changes in disease severity, and implications for diagnostic testing.&#xD;
Although genomic sequencing is the most effective method for mutation detection, it remains&#xD;
time-consuming and expensive process.&#xD;
Aim To present a testing algorithm and evaluate the use of single nucleotide polymorphism (SNP)&#xD;
melting curve PCR for the detection of SARS-CoV-2 lineages, which may inform modifications in&#xD;
public health control and preventive measures, as well as potential adjustments to PCR-based&#xD;
diagnostic tests.&#xD;
Material and methods RNA extracted from 140 SARS-CoV-2 positive samples received in the National Reference Laboratory&#xD;
for Virology, at the Institute of Public Health – Skopje as part of the COVID-19 surveillance system&#xD;
where Ct value ≤ 25 were subjected to SNP testing.&#xD;
Results Analysis of 140 SARS-CoV-2–positive samples collected between January and September 2022&#xD;
using SNP testing revealed a predominance of the BA.4/BA.5 Omicron sublineages, accounting for&#xD;
55.7% of cases.&#xD;
Conclusions Targeted SNP assays enable rapid and accurate detection of mutations associated with specific&#xD;
SARS-CoV-2 Omicron sublineages, facilitating early identification of emerging variants. These results&#xD;
may subsequently be subjected to further investigation, ultimately contributing to an improved&#xD;
public health response.; Abstract Introducere Pandemia de coronavirus reprezintă una dintre cele mai mari crize medicale din ultima vreme, prin&#xD;
urmare, detectarea rapidă a virusului a devenit o normalitate. Pe măsură ce virusul a suferit mutații,&#xD;
apariția de noi variante a dus la modificări ale dinamicii de transmitere și ale severității bolii,&#xD;
precum și remanieri în utilizarea testelor de diagnostic. Cea mai eficientă modalitate de a detecta&#xD;
mutațiile este secvențierea, care este un proces de durată și costisitor.&#xD;
Scop Prezentarea unui algoritm de testare și elaborare a utilizării PCR cu curbă de topire a polimorfismului&#xD;
cu un singur nucleotid (SNP) pentru detectarea tulpinilor SARS-CoV-2, ceea ce poate duce&#xD;
la modificarea măsurilor de control al sănătății publice și a măsurilor preventive, dar și la posibile&#xD;
modificări ale testelor PCR, utilizate pentru detectarea SARS-CoV-2.&#xD;
Material și metode ARN-ul extras din 140 de probe pozitive la SARS-CoV-2 recepționate în Laboratorul Național de Referință&#xD;
pentru Virusologie, la Institutul de Sănătate Publică - Skopje, ca parte a sistemului de supraveghere&#xD;
a COVID-19, unde valoarea Ct ≤ 25 a fost supusă testării SNP.&#xD;
Rezultate Analiza a 140 de probe pozitive la SARS-CoV-2 din ianuarie până în septembrie 2022, utilizând testarea&#xD;
SNP, a identificat o prezență dominantă a subtulpinilor BA.4/BA.5 Omicron, reprezentând 55,7%&#xD;
dintre cazuri.&#xD;
Concluzii Testele SNP specifice permit detectarea rapidă și precisă a mutațiilor legate de o subtulpină specifică&#xD;
a SARS-CoV-2 Omicron, ajutând la identificarea timpurie a variantelor emergente. Rezultatele&#xD;
obținute pot fi supuse, ulterior, unor examinări suplimentare, ceea ce ar putea genera un coeficient&#xD;
mai mare a cazurilor depistate.</summary>
    <dc:date>2026-01-01T00:00:00Z</dc:date>
  </entry>
</feed>

